Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Regulators Contradict Germany's Assessment Of Pfizer Anti-Depressant

Executive Summary

A recent ruling by the European Medicines Agency that the benefit-risk profile of Pfizer Inc.'s antidepressant Endronax (reboxetine) was positive contradicts the outcome of a similar assessment a year ago by German health technology assessment body IQWiG, which had rubbished the drug as “ineffective and potentially harmful.” But it’s far from clear that Pfizer will now have any chance to resurrect the drug in Germany, however.

You may also be interested in...



Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles

France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.

Tweaks To German Pharma Law Require Firms to Prove Drugs' Value Within a Year

Last-minute tweaks to Germany's pharmaceutical sector restructuring laws (AMNOG) require drug firms to provide evidence of a product's value within 12 months of launch – or risk having it struck off the reimbursement list.

Related Content

Topics

UsernamePublicRestriction

Register

PS053814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel